Product Pipeline

Natural killer (NK) cells are vital regulators of immune homeostasis, balancing effective adaptive immune responses with the risk of autoimmune disease development. Abnormalities in NK cell quantity and function are closely linked to the onset, progression, and prognosis of multiple autoimmune diseases. Induced pluripotent stem cell-derived NK cells (iPSC-NK) eliminate CD4+ T cells through TRAIL-mediated apoptosis, thereby reducing T cell-driven autoimmune responses. Activated iPSC-NK cells modulate immune responses by secreting the anti-inflammatory cytokine IL-10, which inhibits T and B lymphocyte proliferation and activation, helping to restore immune homeostasis. iPSC-NK cells further eliminate lymphocytes secreting autoreactive antibodies through mechanisms such as degranulation, cytokine production, and cytotoxicity.

This therapy employs a mixture of immune cells from patients with hepatocellular carcinoma, including γδT cells, NK cells, and iNKT cells. γδT cells demonstrate powerful and multifaceted anti-tumor characteristics; they not only directly kill tumor cells but also exert antibody-dependent cellular cytotoxicity (ADCC) against them. NK cells can rapidly initiate cytotoxic responses without the need for recognizing tumor-specific antigens. iNKT cells integrate essential features of both NK and T cells, functioning as a "bridge" between innate and adaptive immunity and playing a significant role in anti-tumor immune responses. The synergistic effects of these cell types significantly enhance their cytotoxic capabilities. Moreover, these cells express markers such as CD69, CD49a, CD103, CXCR6, and CXCR3, which provide them with liver-homing and liver-resident capabilities, allowing effective accumulation in the liver to target liver cancer cells. These activated killer immune cells express high levels of NKG2D molecules, which can recognize NKG2DL, a receptor highly expressed on liver cancer cells, thereby enhancing their cytotoxic efficiency.